Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer

Lung Cancer

Volumn 90, Issue 1, 2015, Pages 85-91

  Sjøblom, Bjørg ^a,b   Grønberg, Bjørn H ^c,d   Benth, Jurate Šaltyte ^e,f   Baracos, Vickie E ^g   Fløtten, Oystein ^h   Hjermstad, Marianne J ^b,d   Aass, Nina ^b,i   Jordhøy, Marit ^a,i  

^a INNLANDET HOSPITAL TRUST   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF ALBERTA   (Canada)

^h HAUKELAND UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF OSLO   (Norway)

Author keywords

Body composition; Chemotherapy toxicity; Drug therapy; Haematological toxicity; Lean body mass; Non small cell lung cancer; Skeletal muscle; Wasting syndrome

Indexed keywords

GEMCITABINE; NAVELBINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; VINBLASTINE;

ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MUSCLE MASS; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANALOGS AND DERIVATIVES; ANATOMY AND HISTOLOGY; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFECTS; HEMATOLOGIC DISEASE; INDUCTION CHEMOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LUNG NEOPLASMS; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE;

ADMINISTRATION, INTRAVENOUS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CROSS-SECTIONAL STUDIES; DEOXYCYTIDINE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INDUCTION CHEMOTHERAPY; LUNG NEOPLASMS; MALE; MUSCLE, SKELETAL; NEOPLASM STAGING; VINBLASTINE;

EID: 84940956933     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.07.001     Document Type: Article

References (34)

1. Du Bois D., Du Bois E.F. A formula to estimate the approximate surface area if height and weight to be known. Arch. Intern. Med. 1916, 17:863-871.
2. Sawyer M., Ratain M.J. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest. New Drugs 2001, 19(May (2)):171-177. PubMed PMID. 11392451. Epub 2001/06/08.eng.
3. Mathijssen R.H., de Jong F.A., Loos W.J., van der Bol J.M., Verweij J., Sparreboom A. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?. Oncologist 2007, 12(August (8)):913-923. PubMed PMID. 17766650. Epub 2007/09/04. eng.
4. Miller A.A. Body surface area in dosing anticancer agents: scratch the surface!. J. Natl. Cancer Inst. 2002, 24(December (24)):1822-1823. PubMed PMID. 12488468. Epub 2002/12/19. eng.
5. Martin L., Birdsell L., Macdonald N., Reiman T., Clandinin M.T., McCargar L.J., et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 2013, 12(April (12)):1539-1547. PubMed PMID. 23530101. Epub 2013/03/27. eng.
6. Lichtman S.M. Chemotherapy in the elderly. Semin. Oncol. 2004, 31(April (2)):160-174. PubMed PMID. 15112147. Epub 2004/04/28. eng.
7. Prado C.M., Baracos V.E., McCargar L.J., Reiman T., Mourtzakis M., Tonkin K., et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin. Cancer Res. 2009, 8(April (8)):2920-2926. PubMed PMID. 19351764. Epub 2009/04/09. eng.
8. Gusella M., Toso S., Ferrazzi E., Ferrari M., Padrini R. Relationships between body composition parameters and fluorouracil pharmacokinetics. Br. J. Clin. Pharmacol. 2002, 54(August (2)):131-139. PubMed PMID. 12207632. Pubmed Central PMCID: PMC1874401. Epub 2002/09/05. eng.
9. Aslani A., Smith R.C., Allen B.J., Pavlakis N., Levi J.A. he predictive value of body protein for chemotherapy-induced toxicity. Cancer 2000, 4(Feburary (4)):796-803. PubMed PMID. 10679649. Epub 2000/02/19. eng.
10. Morgan D.J., Bray K.M. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin. Pharmacokinet. 1994, 26(4April (4)):292-307. PubMed PMID. 8013162. Epub 1994/04/01. eng.
11. Prado C.M., Baracos V.E., McCargar L.J., Mourtzakis M., Mulder K.E., Reiman T., et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin. Cancer Res. 2007, 11(June (11)):3264-3268. PubMed PMID. 17545532. Epub 2007/06/05. eng.
12. Barret M., Antoun S., Dalban C., Malka D., Mansourbakht T., Zaanan A., et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr. Cancer 2014, 66(4):583-589. PubMed PMID. 24707897. Epub 2014/04/09. eng.
13. Cousin S., Hollebecque A., Koscielny S., Mir O., Varga A., Baracos V.E., et al. Low skeletal muscle is associated with toxicity in patients included in phase I trials. Invest. New Drugs 2014, 32(April (2)):382-387. PubMed PMID. 24343673. Epub 2013/12/18. eng.
14. Morgensztern D., Ng S.H., Gao F., Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J. Thorac. Oncol. 2010, 5(January (1)):29-33. PubMed PMID. 19952801. Epub 2009/12/03. eng.
15. Cufer T., Ovcaricek T., O'Brien M.E. ystemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur. J. Cancer 2013, 49(April (6)):1216-1225. PubMed PMID. 23265700. Epub 2012/12/26. eng.
16. Dawe D.E., Ellis P.M. The treatment of metastatic non-small cell lung cancer in the elderly: an evidence-based approach. Front Oncol. 2014, 4:178. PubMed PMID. 25072026. Pubmed Central PMCID: PMC4091126. Epub 2014/07/30. eng.
17. Sweeney C.J., Zhu J., Sandler A.B., Schiller J., Belani C.P., Langer C., et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001, 92(November (10)):2639-2647. PubMed PMID. 11745199. Epub 2001/12/18. eng.
18. Ross P.J., Ashley S., Norton A., Priest K., Waters J.S., Eisen T., et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?. Br. J. Cancer 2004, 90(May (10)):1905-1911. PubMed PMID. 15138470. Pubmed Central PMCID: PMC2409471. Epub 2004/05/13. eng.
19. Flotten O., Gronberg B.H., Bremnes R., Amundsen T., Sundstrom S., Rolke H., et al. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br. J. Cancer 2012, 24(July (3)):442-447. PubMed PMID. 22759880. Pubmed Central PMCID: PMC3405221. Epub 2012/07/05. eng.
20. Gronberg B.H., Bremnes R.M., Flotten O., Amundsen T., Brunsvig P.F., Hjelde H.H., et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2009, 27(July (19)):3217-3224. PubMed PMID. 19,433,683. Epub 2009/05/13. eng.
21. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., et al. he European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 1993, 85(March (5)):365-376. PubMed PMID.8433390. Epub 1993/03/03. eng.
22. Bergman B., Aaronson N.K., Ahmedzai S., Kaasa S., Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC study group on quality of life. Eur. J. Cancer 1994, 30A(5):635-642. PubMed PMID.8080679. Epub 1994/01/01. eng.
23. Sundstrom S., Bremnes R.M., Brunsvig P., Aasebo U., Kaasa S. Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy?. J. Thorac. Oncol. 2006, 1(October (8)):816-824. PubMed PMID. 17409965. Epub 2007/04/06. eng.
24. Cuyun Carter G., Barrett A.M., Kaye J.A., Liepa A.M., Winfree K.B., John W.J. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manage. Res. 2014, 6:437-449. PubMed PMID. 25364274. Pubmed Central PMCID: PMC4211870. Epub 2014/11/05. eng.
25. Shen W., Punyanitya M., Wang Z., Gallagher D., St-Onge M.P., Albu J., et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J. Appl. Physiol. (Bethesda, Md: 1985) 2004, 97(December (6)):2333-2338. Epub 2004/08/18. eng.
26. Mourtzakis M., Prado C.M., Lieffers J.R., Reiman T., McCargar L.J., Baracos V.E. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab. 2008, 33(October (5)):997-1006. PubMed PMID. 18,923,576. Epub 2008/10/17. eng.
27. Antoun S., Baracos V.E., Birdsell L., Escudier B., Sawyer M.B. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann. Oncol. 2010, 21(August (8)):1594-1598. PubMed PMID. 20,089,558. Epub 2010/01/22. eng.
28. Mir O., Coriat R., Blanchet B., Durand J.P. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 2012, 7(5):e37563. PubMed PMID. 22666367. Pubmed Central PMCID: PMC3364283. Epub 2012/06/06. eng.
29. Huillard O., Mir O., Peyromaure M., Tlemsani C., Giroux J., Boudou-Rouquette P., et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br. J. Cancer 2013, 19(March (5)):1034-1041. PubMed PMID. 23,462,722. Pubmed Central PMCID: PMC3619075. Epub 2013/03/07. eng.
30. Cushen S.J., Power D.G., Teo M.Y., Maceneaney P., Maher M.M., McDermott R., et al. Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib. Am. J. Clin. Oncol. 2014, Published Ahead of print, April 21. PubMed PMID. 24685884. Epub 2014/04/02. Eng.
31. Massicotte M.H., Borget I., Broutin S., Baracos V.E., Leboulleux S., Baudin E., et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J. Clin. Endocrinol. Metab. 2013, 98(June (6)):2401-2408. PubMed PMID. 23543666. Epub 2013/04/02. eng.
32. Tan B.H., Brammer K., Randhawa N., Welch N.T., Parsons S.L., James E.J., et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur. J. Surg. Oncol. 2014, 41(November (3)):26. PubMed PMID. 25498359. Epub 2014/12/17. Eng.
33. Gronberg B.H., Sundstrom S., Kaasa S., Bremnes R.M., Flotten O., Amundsen T., et al. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur. J. Cancer 2010, 46(August (12)):2225-2234. PubMed PMID. 20471248. Epub 2010/05/18. eng.
34. McLeay S.C., Morrish G.A., Kirkpatrick C.M., Green B. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin. Pharmacokinet. 2012, 51(May (5)):319-330. PubMed PMID. 22,439,649. Epub 2012/03/24. eng.